Active Ingredient(s): Tavaborole
FDA Approved: * July 7, 2014
Pharm Company: * ANACOR PHARMS INC
Category: Antifungal

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kerydin Overview

Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole was approved by the US FDA in July 2014.[1] The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection. Contents 1 Medical...

Read more Kerydin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Kerydin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Solution: 5%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kerydin: (2 results)

Sorted by National Drug Code
  • 10337-905 Kerydin 43.5 mg/ml Topical Solution by Pharmaderm, a Division of Fougera Pharmaceuticals Inc.
  • 55724-111 Kerydin 43.5 mg/ml Topical Solution by Anacor Pharmaceuticals, Inc

Other drugs which contain Tavaborole or a similar ingredient: (1 result)